Point Therapeutics

Closed portfolio with an early-phase archive tilt

According to ClinicalTrials.gov-derived indexes, Point Therapeutics sits in the upper quartile of US sponsors by registered trial count (#1,806 of 15,742 sponsors by registered trial count).

7 total trials none currently recruiting 4 completed early-phase tilt upper quartile by trial count

Point Therapeutics: 7 sponsored US clinical trials, none currently recruiting.

Point Therapeutics sponsors 7 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 4 completed. 2 of these trials are in Phase 3-4 (later-stage) and 5 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Skin Cancer, with 1 trials.

Upper-quartile sponsor footprint

Point Therapeutics sits in the upper quartile of the sponsor corpus (#1,806 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.

Indexed trials (enrollment closed)

7 total, page 1 of 1

TERMINATED Phase 3

Study of Talabostat and Pemetrexed vs. Pemetrexed in Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC) After Failure of Platinum-Based Chemotherapy

NCT00290017
TERMINATED Phase 3

Study of Talabostat + Docetaxel Versus Docetaxel in Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC) After Failure of Platinum-Based Chemotherapy

NCT00243204
COMPLETED Phase 2

Study of Talabostat and Cisplatin in Advanced Melanoma

NCT00083252
COMPLETED Phase 2

Study of Talabostat and Rituximab in Advanced Chronic Lymphocytic Leukemia (CLL)

NCT00086203
COMPLETED Phase 2

Study of Talabostat in Advanced Melanoma

NCT00083239
COMPLETED Phase 2

Study of Talabostat and Docetaxel in Advanced Non-Small Cell Lung Cancer

NCT00080080
TERMINATED Phase 2

Trial of Talabostat and Gemcitabine in Patients With Stage IV Adenocarcinoma of the Pancreas

NCT00116389

Phase Distribution

PhaseTrial count
Phase 2 5
Phase 3 2

Therapeutic Areas

Skin Cancer 1
Chronic Lymphocytic Leukemia 1
Melanoma 1

How the Point Therapeutics early-phase archive is shaped

7 indexed studies, none listed as recruiting (0% open); 4 completed (57%).

Phase mix: 2 late (III/IV) vs 5 early (I/II) (early-phase heavy).

Top condition: Skin Cancer (1 trial), 2 others listed.

How to read a closed sponsor archive

When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.

Point Therapeutics: archived-pipeline peers nationwide

Peers matched on 7 indexed studies with no current recruiting: volume and archive shape, not condition overlap.

Point Therapeutics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 051015 0%10%20%30%40% Total trials Recruiting share Point Therapeutics3M4Life Research89bioAbbott Diagnostics Division10xBio22nd Century Group23andMe3-C Institute for Social Development
Point Therapeutics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Point Therapeutics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 7 archived trials

Sponsors with similar archive density (± trial count)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Point Therapeutics page

7 registered trials is a research-attention snapshot, not an endorsement of Point Therapeutics or any single study.

  • None of Point Therapeutics's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
  • Skin Cancer is the condition Point Therapeutics studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Skin Cancer trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Point Therapeutics pipeline card: 7 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.